Rep. Cory Mills (R-FL) sent a letter Tuesday to the chairman of Sichuan Kelun-Biotech Biopharmaceutical, Mr. Liu Gexin, "demanding answers to serious allegations regarding their ties to the Chinese C ...

The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

After the Red No. 3 ban, there are now eight color additives approved by the FDA. They are FD&C Blue No. 1, FD&C Blue No. 2, ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...